EUVIMEDOpdag EUVIMED
LeserbriefOpen access · CC BY-NC-ND 4.0

Genetic Code Expansion for Site-Specific Labeling of Antibodies with Radioisotopes

Christine Koehler, Paul F Sauter, Benedikt Klasen, Christopher Waldmann, Stefanie Pektor, Nicole Bausbacher, Edward A Lemke iD, Matthias Miederer

ACS Chemical Biology · 2023

DOI: 10.1021/acschembio.2c00634 ↗

At a glance

Leserbrief in ACS Chemical Biology, 2023. Written by Christine Koehler and 7 co-authors. Institution: VERAXA Biotech GmbH, Carl-Friedrich Gauß-Ring 5, 69124 Heidelberg, Germany. Major MEDLINE topics: Radioisotopes, Immunoconjugates. Cited 14 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: H2020 European Research Council, VERAXA Biotech GmbH.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Due to their target specificity, antibody-drug conjugates─monoclonal antibodies conjugated to a cytotoxic moiety─are efficient therapeutics that can kill malignant cells overexpressing a target gene. Linking an antibody with radioisotopes (radioimmunoconjugates) enables powerful diagnostics and/or closely related therapeutic applications, depending on the isotope. To generate site-specific radioimmunoconjugates, we utilized genetic code expansion and subsequent conjugation by inverse electron-demand Diels-Alder cycloaddition reactions. We show that, using this approach, site-specific labeling of trastuzumab with either zirconium-89 (89Zr) for diagnostics or lutetium-177 (177Lu) for therapeutics yields efficient radioimmunoconjugates. Positron emission tomography imaging revealed a high accumulation of site-specifically 89Zr-labeled trastuzumab in tumors after 24 h and low accumulation in other organs. The corresponding 177Lu-trastuzumab radioimmunoconjugates were comparably distributed in vivo.

Subjects

MeSH terms (MEDLINE)

RadioisotopesImmunoconjugatesPositron-Emission TomographyAntibodies, MonoclonalTrastuzumabCell Line, TumorIsotope Labeling

Substances

RadioisotopesAntibodies, MonoclonalTrastuzumabImmunoconjugates

Authors and institutions

  • VERAXA Biotech GmbH, Carl-Friedrich Gauß-Ring 5, 69124 Heidelberg, Germany.
  • Structural and Computational Biology Unit, European Molecular Biology Laboratory, Meyerhofstrasse 1, 69117 Heidelberg, Germany.
  • Department of Chemistry, TRIGA site, Johannes Gutenberg University, Fritz-Strassmann-Weg 2, 55128 Mainz, Germany.
  • Department of Nuclear Medicine, University Medical Center, Johannes Gutenberg University Langenbeckstraße 1, 55131 Mainz, Germany.
  • BIOCENTER, Johannes Gutenberg University, Hanns-Dieter-Hüsch-Weg 17, 55128 Mainz, Germany.
  • IMB Institute of Molecular Biology, gGmbH, Ackermannweg 4, 55128 Mainz, Germany.

ORCID profiles: Edward A Lemke

Funding

  • H2020 European Research Council
  • VERAXA Biotech GmbH

Cite

APA

Koehler, C., Sauter, P. F., Klasen, B., Waldmann, C., Pektor, S., Bausbacher, N., Lemke, E. A., & Miederer, M. (2023). Genetic Code Expansion for Site-Specific Labeling of Antibodies with Radioisotopes. ACS Chemical Biology. https://doi.org/10.1021/acschembio.2c00634

Vancouver

Koehler C, Sauter PF, Klasen B, Waldmann C, Pektor S, Bausbacher N, et al. Genetic Code Expansion for Site-Specific Labeling of Antibodies with Radioisotopes. ACS Chemical Biology. 2023. doi:10.1021/acschembio.2c00634

BibTeX
@article{Koehler2023,
  author = {Koehler, Christine and Sauter, Paul F and Klasen, Benedikt and Waldmann, Christopher and Pektor, Stefanie and Bausbacher, Nicole and Lemke, Edward A and Miederer, Matthias},
  title = {Genetic Code Expansion for Site-Specific Labeling of Antibodies with Radioisotopes},
  journal = {ACS Chemical Biology},
  year = {2023},
  doi = {10.1021/acschembio.2c00634}
}
Start for free →